Should NSCLC Patients Receive Immunotherapy ' Indefinitely ' ? Should NSCLC Patients Receive Immunotherapy ' Indefinitely ' ?

Most long-term responders to immunotherapy continue taking the drugs after 2 years. But data show long-term use likely offers no survival benefit.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news